Ionis Pharmaceuticals’ Tryngolza (olezarsen) gained wider U.S. approval for severe hypertriglyceridemia, moving the therapy from a rare formulation into a more prevalent-market label. The FDA approval builds on Phase 3 results and carries regulatory advantages including priority review and breakthrough therapy designation. The expansion strengthens Ionis’s pivot toward developing and commercializing its own cardiometabolic assets rather than relying on partnerships alone. It also likely changes payer expectations around testing intensity and access controls, given broader patient eligibility. For investors, the label expansion is the clearest near-term driver after years of focusing on antisense franchise execution and manufacturing readiness for broader chronic use.